Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Spyre Therapeutics (SYRE) Enterprise Value: 2015-2025

Historic Enterprise Value for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $526.1 million.

  • Spyre Therapeutics' Enterprise Value fell 51.27% to $526.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 billion, marking a year-over-year decrease of 585.92%. This contributed to the annual value of $594.2 million for FY2024, which is 335.67% up from last year.
  • As of Q3 2025, Spyre Therapeutics' Enterprise Value stood at $526.1 million, which was up 6.85% from $492.4 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Enterprise Value ranged from a high of $1.1 billion in Q3 2024 and a low of -$252.1 million during Q4 2023.
  • Moreover, its 3-year median value for Enterprise Value was $492.4 million (2025), whereas its average is $334.5 million.
  • Per our database at Business Quant, Spyre Therapeutics' Enterprise Value slumped by 799.32% in 2023 and then skyrocketed by 4,643.36% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Enterprise Value (Quarterly) stood at $141.1 million in 2021, then crashed by 119.86% to -$28.0 million in 2022, then plummeted by 799.32% to -$252.1 million in 2023, then soared by 335.67% to $594.2 million in 2024, then crashed by 51.27% to $526.1 million in 2025.
  • Its Enterprise Value was $526.1 million in Q3 2025, compared to $492.4 million in Q2 2025 and $211.3 million in Q1 2025.